X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs SUN PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB SUN PHARMA DR. REDDYS LAB/
SUN PHARMA
 
P/E (TTM) x 26.3 41.9 62.8% View Chart
P/BV x 3.2 3.3 99.8% View Chart
Dividend Yield % 0.8 0.4 209.2%  

Financials

 DR. REDDYS LAB   SUN PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
SUN PHARMA
Mar-18
DR. REDDYS LAB/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,788701 398.0%   
Low Rs1,902433 439.0%   
Sales per share (Unadj.) Rs860.8110.4 779.6%  
Earnings per share (Unadj.) Rs57.111.0 519.9%  
Cash flow per share (Unadj.) Rs122.017.2 708.1%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %0.90.4 241.7%  
Book value per share (Unadj.) Rs757.7158.8 477.2%  
Shares outstanding (eoy) m165.912,399.26 6.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.75.1 53.1%   
Avg P/E ratio x41.151.6 79.6%  
P/CF ratio (eoy) x19.232.9 58.4%  
Price / Book Value ratio x3.13.6 86.7%  
Dividend payout %35.018.2 192.4%   
Avg Mkt Cap Rs m389,0341,360,021 28.6%   
No. of employees `00023.517.8 132.2%   
Total wages/salary Rs m32,14953,671 59.9%   
Avg. sales/employee Rs Th6,070.814,890.9 40.8%   
Avg. wages/employee Rs Th1,366.63,017.1 45.3%   
Avg. net profit/employee Rs Th402.51,480.6 27.2%   
INCOME DATA
Net Sales Rs m142,810264,895 53.9%  
Other income Rs m1,5528,388 18.5%   
Total revenues Rs m144,362273,282 52.8%   
Gross profit Rs m23,51256,081 41.9%  
Depreciation Rs m10,77214,998 71.8%   
Interest Rs m7885,176 15.2%   
Profit before tax Rs m13,50444,295 30.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m4,3808,452 51.8%   
Profit after tax Rs m9,46826,338 35.9%  
Gross profit margin %16.521.2 77.8%  
Effective tax rate %32.419.1 170.0%   
Net profit margin %6.69.9 66.7%  
BALANCE SHEET DATA
Current assets Rs m104,984316,359 33.2%   
Current liabilities Rs m68,938198,643 34.7%   
Net working cap to sales %25.244.4 56.8%  
Current ratio x1.51.6 95.6%  
Inventory Days Days7495 78.4%  
Debtors Days Days104108 96.2%  
Net fixed assets Rs m104,385213,178 49.0%   
Share capital Rs m8302,399 34.6%   
"Free" reserves Rs m124,886378,606 33.0%   
Net worth Rs m125,716381,006 33.0%   
Long term debt Rs m25,08917,721 141.6%   
Total assets Rs m225,443643,028 35.1%  
Interest coverage x18.19.6 189.8%   
Debt to equity ratio x0.20 429.1%  
Sales to assets ratio x0.60.4 153.8%   
Return on assets %4.54.9 92.8%  
Return on equity %7.56.9 108.9%  
Return on capital %9.710.0 96.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m72,62340,816 177.9%   
Fx outflow Rs m18,91630,143 62.8%   
Net fx Rs m53,70710,673 503.2%   
CASH FLOW
From Operations Rs m18,03039,072 46.1%  
From Investments Rs m-14,883-33,708 44.2%  
From Financial Activity Rs m-4,440-15,393 28.8%  
Net Cashflow Rs m-1,236-7,359 16.8%  

Share Holding

Indian Promoters % 25.5 63.7 40.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 5.1 105.3%  
FIIs % 35.3 23.0 153.5%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 8.3 184.3%  
Shareholders   75,885 133,026 57.0%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   SHASUN PHARMA  CIPLA  ABBOTT INDIA  FULFORD INDIA  WYETH LTD  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.

Related Views on News

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Nov 15, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS